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Glycoprotein IIb/IIIa Inhibitors
Do They Still Have a Role?*
Deepak L. Bhatt, MD, MPH
Boston, Massachusetts
Compared with aspirin plus unfractionated heparin, the
addition of intravenous glycoprotein IIb/IIIa inhibitors
(GPIs) represented a major advance in percutaneous coro-
nary intervention (PCI). The benefits were particularly
notable in high-risk patients, such as those with acute
coronary syndromes or diabetes (1,2). The potent platelet
blockade afforded by these agents consistently reduced
periprocedural ischemic complications, including myocar-
dial infarction (MI). Their necessity, however, in the con-
text of stenting with concomitant adenosine diphosphate
(ADP) receptor antagonism has been challenged, especially
during elective PCI.
See page 1190
In this issue of the Journal, Winchester et al. (3) have
erformed a rigorous meta-analysis of the available data to
ddress whether GPIs provide incremental benefit during
onurgent PCI in patients receiving stents and ADP
lockers. Nonfatal MI at 30 days was reduced from 8.3% to
.1%. This one-third reduction was highly statistically
ignificant and was similar for abciximab and for small-
olecule GPIs. Although one might have hypothesized that
he effect would be larger in patients without thienopyridine
re-treatment, no effect modification was noted. Similarly,
hen year of publication was examined in a meta-regression
nalysis, the benefit of GPIs was similar in the more recent
tudies compared with the older studies—in contradistinc-
ion to the prevailing sentiment in the clinical community.
hus, compared with heparin, GPIs provide a similar
egree of benefit now as they did a decade ago, and the
arked drop in their use may not be entirely justified.
The reduction in target vessel revascularization at 30 days
n the analysis by Winchester et al. (3) was not significant.
he increase in major bleeding was not significant, although
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Aventis, and The Medicines Company.the increase in minor bleeding from 1.7% to 3.0% was
highly significant. Of note, the definition of minor bleeding
that was used included forms of bleeding that many clini-
cians (and patients) may not deem truly minor in the present
era. Thrombocytopenia also was increased significantly with
GPIs (particularly abciximab), but reassuringly, the rate of
stroke was not significantly higher.
Mortality was examined at 30 days and was not signifi-
cantly lower in those patients randomized to GPIs; in the
subset of patients for whom mortality rates were available at
1 year, the same pattern was seen. Rates of mortality after
elective PCI are relatively low, and with a much larger
sample of patients, perhaps the observed mortality difference
would have become statistically significant. Potentially,
longer follow-up would be necessary to see if the reductions
in periprocedural MI translated into an impact on left
ventricular function or on mortality. Alternatively, the
increases in minor bleeding (which, as mentioned above,
were not so minor) may have offset to an extent the benefits
expected from the decreases in MI. Periprocedural MI as an
end point has been controversial (4–6). Uncertainty re-
mains over the exact threshold at which a periprocedural MI
“counts,” and harder end points such as Q-wave MI and
death have not always tracked with periprocedural MI,
although this in part may be because of the definition used.
ADP receptor blockade clearly has a profound influence
on periprocedural outcomes, and a recent meta-analysis
showed that even more potent ADP blockers than standard-
dose clopidogrel have further impact (7). Thus, the incre-
mental value of GPIs in the setting of the more potent ADP
blocking strategies remains to be determined. Therapies
other than conventional antithrombotics, such as statins,
have been shown to reduce periprocedural MI, potentially
further reducing the impact of GPIs (8,9). However, there
is no reason to think that the benefits of statin pre-
treatment would not be complementary to GPIs.
The emerging data regarding bivalirudin with bailout use
of GPIs provide a further challenge to routine use of GPI
blockade (10,11). Consistently, bivalirudin has decreased
bleeding complications compared with GPIs, while provid-
ing slightly less protection against periprocedural MI
(12–15). Sophisticated analyses have shown that the impact
of significant bleeding at least equals and may surpass that of
small periprocedural MIs (16,17). The relationships be-
tween bleeding and outcome are similar to those between
periprocedural MI and outcome—partially explained by
confounding and partially explained by direct causation,
with the ratio depending on the magnitude of the event.
That is, a large bleed or MI likely can lead to subsequent
ischemic events including death, whereas a very small bleed
or MI is unlikely to be directly causative. Regardless, the
data show that bivalirudin with provisional GPI use com-
pared with routine GPI use is associated with lower mor-
tality at 1 year in acute MI patients undergoing PCI, which
is particularly comforting when using bivalirudin in patients
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PCI (18).
Although one could make a cogent argument for substi-
tuting bivalirudin routinely for GPIs based on randomized
clinical trial and registry data at the current time, the field of
GPIs has not remained entirely static, either. Shorter
infusions may provide a similar degree of benefit as longer
infusions, although further large-scale study is needed (19).
Additionally, intracoronary infusion of GPIs (comparative
trials of which were excluded from the present meta-
analysis) may have greater efficacy and safety compared with
intravenous infusion, and this approach currently is being
studied (20). Costs also may drop. Radial access decreases
the absolute rate of bleeding substantially, allowing more
potent antithrombotic strategies to be reconsidered. Thus,
in the future, there may yet be a renaissance of GPIs.
The analysis by Winchester et al. reminds us not to
discard older drugs simply because they are older. Of course,
data continuously need to be reevaluated as additional
clinical trial and registry data are published. Nevertheless,
this meta-analysis demonstrates that even on a background
of aspirin, standard thienopyridine regimens, and heparin—
the PCI cocktail most commonly used worldwide—GPIs
continue to have an important potential role. Notably, this
data set further validates the concept that additional platelet
inhibition is warranted beyond that provided by aspirin and
standard-dose thienopyridines. Whether this in fact will be
GPIs or one of the novel antiplatelet regimens remains to
be seen.
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